Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Avectas

Main focus: Next-generation delivery technology for gene editing

Company stage: Pre-clinical

Diseases: Cancer

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Dublin, Ireland

Website: https://avectas.com/

Partners: ONK Therapeutics

Avectas develops its proprietary SOLUPORE® technology to genetically engineer T cells and natural killer (NK) cells to enable the next generation of gene-modified cell therapies. The company has established a collaboration with ONK Therapeutics, however, it yet has to disclose any proprietary or partnered therapeutic programmes.

Tags

HashtagAvectas

Company: Avectas
close
Search CRISPR Medicine